Postpartum Depression Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited

Postpartum Depression Pipeline constitutes 10+ key companies continuously working towards developing 10+ Postpartum Depression treatment therapies, analyzes DelveInsight.

Postpartum Depression Overview:

Postpartum depression (PPD) is a significant health concern that affects approximately 15% of women after childbirth. It can have serious negative effects on their children as well. The symptoms and risk factors of PPD closely resemble those of non-postpartum depression, but PPD is specifically triggered by postpartum-related factors, particularly hormonal fluctuations. Diagnosis is typically conducted using a questionnaire in a clinical setting. Treatment often includes psychotherapy and antidepressant medications. The symptoms of PPD mirror those of non-puerperal depression, with the added context of recent childbirth. Common symptoms include a persistently low mood, loss of interest, sleep disturbances, appetite changes, feelings of worthlessness, difficulty concentrating, and suicidal thoughts. Anxiety is also frequently reported. In severe cases, PPD may involve psychotic symptoms such as delusions and auditory hallucinations, including voices instructing harm to the infant.

Request for a detailed insights report on Postpartum Depression pipeline insights @ https://www.delveinsight.com/report-store/postpartum-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Postpartum Depression Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Postpartum Depression Therapeutics Market.

Key Takeaways from the Postpartum Depression Pipeline Report

DelveInsight's Postpartum Depression pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Postpartum Depression treatment.
Key Postpartum Depression companies such as GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others are evaluating new drugs for Postpartum Depression to improve the treatment landscape.
Promising Postpartum Depression pipeline therapies in various stages of development include RE-104, GH001, BRII-297, and others.

Recent breakthroughs in the Postpartum Depression Pipeline Segment:

​In August 2023, the U.S. Food and Drug Administration (FDA) approved Zurzuvae (zuranolone), marking the first oral medication sanctioned for the treatment of postpartum depression (PPD) in adults. This approval offers a significant advancement over previous treatments, which were limited to intravenous injections administered in healthcare facilities. Zurzuvae is designed as a once-daily pill taken over a 14-day period, with patients reporting symptom improvement as early as day three. ​

Postpartum Depression Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Postpartum Depression Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postpartum Depression treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postpartum Depression market.

Download our free sample page report on Postpartum Depression pipeline insights @ https://www.delveinsight.com/sample-request/postpartum-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Postpartum Depression Emerging Drugs

RE-104: Reunion Neuroscience
GH001: GH Research
BRII-297: Brii Bio

Postpartum Depression Companies

There are over 10 key companies actively developing therapies for postpartum depression. Among them, Reunion Neuroscience has a drug candidate in the most advanced stage of development, currently in Phase II clinical trials.

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Postpartum Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Postpartum Depression Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Postpartum Depression Therapies and Key Companies: Postpartum Depression Clinical Trials and advancements @ https://www.delveinsight.com/report-store/postpartum-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Postpartum Depression Pipeline Therapeutic Assessment
• Postpartum Depression Assessment by Product Type
• Postpartum Depression By Stage
• Postpartum Depression Assessment by Route of Administration
• Postpartum Depression Assessment by Molecule Type

Download Postpartum Depression Sample report to know in detail about the Postpartum Depression treatment market @ Postpartum Depression Therapeutic Assessment @ https://www.delveinsight.com/sample-request/postpartum-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Postpartum Depression Current Treatment Patterns
4. Postpartum Depression - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Postpartum Depression Late-Stage Products (Phase-III)
7. Postpartum Depression Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Postpartum Depression Discontinued Products
13. Postpartum Depression Product Profiles
14. Postpartum Depression Key Companies
15. Postpartum Depression Key Products
16. Dormant and Discontinued Products
17. Postpartum Depression Unmet Needs
18. Postpartum Depression Future Perspectives
19. Postpartum Depression Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Postpartum Depression Pipeline Reports Offerings: https://www.delveinsight.com/report-store/postpartum-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.